Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4575	SERIAL NO. 09/765,086
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 17, 2001	GROUP: 1646

OIPE DEC 0 3 2001 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
MY		5,622,699	04/22/97	Ruoslahti and Pasqualini			
		5,789,542	08/04/98	McLaughlin and Becker			
		6,180,084	01/30/01	Ruoslahti and Pasqualini			
V		6,232,287	05/15/01	Ruoslahti et al.			

Alt Continuation-in-Part and Class and Subclass

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
MY	V	WO 97/10507	03/20/97	PCT			
	V	WO 97/26918	07/31/97	PCT			
	V	WO 98/10795	03/19/98	PCT			
	V	WO 99/46284	09/16/99	PCT			
	V	WO 00/42973	07/27/00	PCT			
V							

EXAMINER	DATE CONSIDERED
Misook J	5/13/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4575	SERIAL NO. 09/765,086
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 17, 2001	GROUP: 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

my	✓	Alvarez-Bravo et al., "Novel synthetic antimicrobial peptides effective against methicillin-resistant *Staphylococcus aureus*," Biochem. J. 302:535-538 (1994)
	✓	Barinaga, "Peptide-Guided Cancer Drugs Show Promise in Mice," Science 279:323-324 (1998) their own work
	✓	Bessalle et al., "All-D-magainin: chirality, antimicrobial activity and proteolytic resistance," FEBS Lett. 274:151-155 (1990)
	✓	Blondelle and Houghten, "Design of model amphipathic peptides having potent antimicrobial activities," Biochem. 31:12688-12694 (1992)
	✓	Blondelle and Houghten in Bristol (Ed.), Annual Reports in Medicinal Chemistry, pp. 159-168, Academic Press, San Diego, CA (1992)
	✓	Carter et al., "Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase," Proc. Natl. Acad. Sci. USA 93:749-753 (1996)
	✓	Daher and Beaini, "Prostate-specific antigen and new related markers for prostate cancer," Clinical Chemistry Laboratory Medicine 36:671-81 (1998)
	✓	Decaudin et al., "Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy (Review)," International Journal of Oncology 12:141-151 (1998)
	✓	Dowling and Tannock, "Systemic treatment for prostate cancer," Cancer Treatment Reviews 24:283-301 (1998)
✓	✓	Ellerby et al., "Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases," J. Neurosci. 17:6165-6178 (1997)

EXAMINER	DATE CONSIDERED
Mirsky	5/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4575	SERIAL NO. 09/765,086
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 17, 2001	GROUP: 1646

my	✓	Ellerby et al., "Anti-cancer activity of targeted pro-apoptotic peptides," Database Accession Number: PREV199900484607, Abstract (1999)
	✓	Ellerby et al., "Anti-cancer activity of targeted pro-apoptotic peptides," Nature Medicine 5:1032-1038 (1999)
	✓	Hovius et al., "Phospholipid asymmetry of the outer membrane of rat liver mitochondria. Evidence for the presence of cardiolipin on the outside of the outer membrane," FEBS Lett. 330:71-76 (1993)
	✓	Jacobson et al., "Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease," Nature Medicine 2:482-484 (1996)
	✓	Jain, "Vascular and interstitial barriers to delivery of therapeutic agents in tumors," Cancer and Metastasis Reviews 9:253-266 (1990)
	✓	Janeway et al., Immunobiology: The Immune System in Health and Disease pp. 13:18-13:19, Garland Publishing Inc., New York (1997)
	✓	Javadpour and Barkley, "Self-assembly of designed antimicrobial peptides in solution and micelles," Database Accession Number: PREV199799701983XP002164831, Abstract (1997)
	✓	Javadpour and Barkley, "Self-assembly of designed antimicrobial peptides in solution and micelles," Biochemistry 36:9540-9549 (1997)
	✓	Javadpour et al., "De novo antimicrobial peptides with low mammalian cell toxicity," Database Accession Number: PREV199699130909XP002164830, Abstract (1996)
	✓	Javadpour et al., "De novo antimicrobial peptides with low mammalian cell toxicity," J. Med. Chem. 39:3107-3113 (1996)
✓	✓	Kroemer et al., "Mitochondrial control of apoptosis," Immunology Today 1:44-57 (1997)

EXAMINER	DATE CONSIDERED
Misook J	5/16/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4575	SERIAL NO. 09/765,086
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 17, 2001	GROUP: 1646

my	✓	Liu et al., "Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen Also React with Tumor Vascular Endothelium," Cancer Research 57:3629-3634 (1997)
	✓	Lugtenberg and van Alphen, "Molecular architecture and functioning of the outer membrane of *Escherichia coli* and other gram-negative bacteria," Biochim. Biophys. Acta 737:51-115 (1983)
	✓	Maloy and Kari, "Structure-activity studies on magainins and other host defense peptides," Biopolymers 37:105-122 (1995)
	✓	Mancheno et al., "A peptide of nine amino acid residues from alpha-sarcin cytotoxin is a membrane-perturbing structure," J. Peptide Res. 51:142-148 (1998)
	✓	Matsuzaki et al., "Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore," Biochemistry 34:6521-6526 (1995)
	✓	McLean et al., "Minimal peptide length for interaction of amphipathic alpha-helical peptides with phosphatidylcholine liposomes," Biochemistry 30:31-37 (1991)
	✓	Pasqualini and Ruoslahti, "Organ targeting *in vivo* using phage display peptide libraries," Nature 380:364-366 (1996)
	✓	Pfeiffer et al., "The Peptide Mastoparan Is a Potent Facilitator of the Mitochondrial Permeability Transition," The Journal of Biological Chemistry 270:4923-4932 (1996)
	✓	Saberwal and Nagaraj, "Cell-lytic and antibacterial peptides that act by perturbing the barrier function of membranes: facets of their conformational features, structure-function correlations and membrane-perturbing abilities," Biochim. Biophys. Acta 1197:109-131 (1994)
↓	✓	Sciavolino and Abate-Shen, "Molecular biology of prostate development and prostate cancer," Ann. Medicine 30:357-68 (1998)

EXAMINER	DATE CONSIDERED
Mirsky	5/16/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4575	SERIAL NO. 09/765,086
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 17, 2001	GROUP: 1646

mg	✓	Wade et al., "All-D amino acid-containing channel-forming antibiotic peptides," Proc. Natl. Acad. Sci. USA 87:4761-4765 (1990)
L	✓	Zamzami et al., "Mitochondrial Implication in Accidental and Programmed Cell Death: Apoptosis and Necrosis," Journal of Bioenergetics and Biomembranes 29:185-193 (1997)

EXAMINER	DATE CONSIDERED
Misook J	5/16/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat